NXP900 clinical trials
NXP900 is named as an intervention in 3 current clinical trials in our USA and UK registers. 2 are recruiting patients now. All registered phases are Phase 1. The lead sponsor is Nuvectis Pharma, Inc. The most-studied condition is Advanced Solid Tumor.
How NXP900 works
All drug targets →- Non-small cell lung carcinomaPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3824089, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for NXP900
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of NXP900
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
NCT07315113 · EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients
|
Phase 1 | Recruiting | Nuvectis Pharma, Inc | USA |
|
Study of NXP900 With Lorlatinib in ALK+ Lung Cancer
NCT07784959 · ALK Positive, ALK Positive Non-small Cell Lung Cancer, NSCLC
|
Phase 1 | Recruiting | Nuvectis Pharma, Inc | USA |
|
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
NCT05873686 · Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer
|
Phase 1 | Active, closed | Nuvectis Pharma, Inc | UK, USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with NXP900
10 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Nuvectis Pharma, Inc | 3 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 2 |
| Clinical trials in UK | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about NXP900 trials
How many clinical trials are testing NXP900?
3 current trials in our USA and UK registers name NXP900 as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are NXP900 trials recruiting patients?
Yes. 2 of the 3 trials are recruiting: 2 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors NXP900 clinical trials?
The lead sponsor is Nuvectis Pharma, Inc. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how NXP900 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how NXP900 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists NXP900 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.